Investors

Growing Shareholder Value

Press Releases

Abiomed to Hold Fireside Chat at the William Blair 40th Annual Growth Stock Conference

Jun 03, 2020
Read More
Additional Formats
PDF Version

FDA Issues Emergency Use Authorization for Impella RP as Therapy for COVID-19 Patients with Right Heart Failure

Jun 01, 2020
Read More
Additional Formats
PDF Version

Abiomed to Hold Fireside Chat at Jefferies Virtual Healthcare Conference

May 27, 2020
Read More
Additional Formats
PDF Version

Abiomed to Host Virtual Clinical Data and Innovation Day

May 20, 2020
Read More
Additional Formats
PDF Version

PROTECT III Study Shows Placing Impella Prior to High-Risk PCI is Associated with Lower Mortality Compared to Bailout PCI

May 19, 2020
Read More
Additional Formats
PDF Version

Abiomed Announces Q4 FY 2020 Revenue of $207 Million and 28.1% Operating Margin

Apr 30, 2020
Read More
Additional Formats
PDF Version

Abiomed Expands Product Portfolio with Acquisition of Cardiopulmonary Support Technology (ECMO) to Improve Outcomes for Patients

Apr 29, 2020
Read More
Additional Formats
PDF Version

Abiomed Fourth Quarter Fiscal 2020 Earnings and Conference Call Notification

Apr 10, 2020
Read More
Additional Formats
PDF Version

Abiomed’s Response to the COVID-19 Pandemic

Mar 25, 2020
Read More
Additional Formats
PDF Version

Study of 21,848 High-Risk PCI Patients Demonstrates Lower Risk of Death and Complications in Patients who Receive PVADs (Impella)

Mar 04, 2020
Read More
View all